請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/19410
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 張淑惠(Shu-Hui Chang) | |
dc.contributor.author | Min-Tzu Li | en |
dc.contributor.author | 李敏慈 | zh_TW |
dc.date.accessioned | 2021-06-08T01:57:43Z | - |
dc.date.copyright | 2020-08-27 | |
dc.date.issued | 2020 | |
dc.date.submitted | 2020-08-17 | |
dc.identifier.citation | 1. Wolf, P., Abbott, R., Kannel, W. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke.1991, 22(8), 983-988. 2. Belmar Vega, L., de Francisco, Á., Bada da Silva, J., Galván Espinoza, L., Fernández Fresnedo, G. New oral anticoagulants in patients with chronic kidney disease. Nefrología. 2017, 37(3), 244-252. 3. Jain, N., Reilly, R. Clinical Pharmacology of Oral Anticoagulants in Patients with Kidney Disease. Clinical Journal of the American Society of Nephrology.2018, 14(2), 278-287. 4. Steffel, J., Verhamme, P., Potpara, T., Albaladejo, P., Antz, M., Desteghe, L. et al. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. European Heart Journal.2018, 39(16), 1330-1393. 5. García Rodríguez, L., Martín-Pérez, M., Vora, P., Roberts, L., Balabanova, Y., Brobert, G. et al. Appropriateness of initial dose of non-vitamin K antagonist oral anticoagulants in patients with non-valvular atrial fibrillation in the UK. British Medical Journal Open 2019;9:e031341. 6. Steinberg, B., Shrader, P., Pieper, K., Thomas, L., Allen, L., Ansell, J. et al. Frequency and Outcomes of Reduced Dose Non–Vitamin K Antagonist Anticoagulants: Results From ORBIT‐Af II (The Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II). Journal of the American Heart Association. 2018, 7(4). 7. Jacobs, M., van Hulst, M., Campmans, Z., Tieleman, R. Inappropriate non-vitamin K antagonist oral anticoagulants prescriptions: be cautious with dose reductions. Netherlands Heart Journal.2019, 27(7-8), 371-377. 8. Yao, X., Shah, N., Sangaralingham, L., Gersh, B., Noseworthy, P. Non–Vitamin K Antagonist Oral Anticoagulant Dosing in Patients With Atrial Fibrillation and Renal Dysfunction. Journal of the American College of Cardiology. 2017, 69(23), 2779-2790. 9. Shrestha, S., Baser, O., Kwong, W. Effect of Renal Function on Dosing of Non–Vitamin K Antagonist Direct Oral Anticoagulants Among Patients With Nonvalvular Atrial Fibrillation. Annals of Pharmacotherapy. 2018, 52(2) 147–153. 10. Lee, S., Lee, Y., Park, J., Cha, M., Kim, T., Park, J. et al. Label Adherence for Non-Vitamin K Antagonist Oral Anticoagulants in a Prospective Cohort of Asian Patients with Atrial Fibrillation. Yonsei Medical Journal.2019, 60(3), 277-284. 11. Wang, K., Giugliano, R., Goto, S., Chiu, C., Lin, C., Lai, E., Chiang, C. Standard dose versus low dose non–vitamin K antagonist oral anticoagulants in Asian patients with atrial fibrillation: A meta-analysis of contemporary randomized controlled trials. Heart Rhythm.2016, 13(12), 2340-2347. 12. Lee, S., Choi, E., Han, K., Jung, J., Cha, M., Oh, S., Lip, G. Non–Vitamin K Antagonist Oral Anticoagulants in Asian Patients With Supranormal Renal Function. Stroke.2019, 50(6), 1480-1489. 13. Chan, Y., See, L., Tu, H., Yeh, Y., Chang, S., Wu, L. et al. Efficacy and Safety of apixaban, dabigatran, rivaroxaban, and warfarin in Asians With Nonvalvular Atrial Fibrillation. Journal of the American Heart Association.2018, 7(8). 14. Lee, K., Choi, J., Boo, K., Kim, D., Kim, Y., Oh, S. et al. Effectiveness and Safety of Off-label Dosing of Non–vitamin K Antagonist Anticoagulant for Atrial Fibrillation in Asian Patients. Scientific Reports.2020, 10(1). 15. Chiang CE, Wang KL, Lip GY. Stroke prevention in atrial fibrillation: an Asian perspective. Thromb Haemost 2014; 111(5): 789-97. 16. Kannel, W., Abbott, R., Savage, D., McNamara, P. Epidemiologic Features of Chronic Atrial Fibrillation. New England Journal Of Medicine.1987, 306(17), 1018-1022. 17. Lip GY , Brechin CM , Lane DA . The global burden of atrial fibrillation and stroke: a systematic review of the epidemiology of atrial fibrillation in regions outside North America and Europe. Chest. 2012 ; 142(6): 1489 - 1498 . 18. Guo Y, Tian Y, Wang H, Si Q, Wang Y, Lip GY. Prevalence, incidence, and lifetime risk of atrial fibrillation in China: new insights into the global burden of atrial fibrillation. Chest. 2015;147(1):109-119. 19. Chao, T., Liu, C., Tuan, T., Chen, T., Hsieh, M., Lip, G., Chen, S. Lifetime Risks, Projected Numbers, and Adverse Outcomes in Asian Patients With Atrial Fibrillation. Chest. 2018; 153(2):453-466 20. Iwasaki, Y., Nishida, K., Kato, T., Nattel, S. Atrial Fibrillation Pathophysiology. Circulation.2011 , 124(20), 2264-2274. 21. January, C., Wann, L., Alpert, J., Calkins, H., Cigarroa, J., Cleveland, J. et al. (2014). 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation. Journal of the American College Of Cardiology.2014, 64(21), e1-e76. 22. MacRae, C. Symptoms in Atrial Fibrillation. Circulation: Arrhythmia and Electrophysiology. 2009, 2(3), 215-217. 23. Wood, A., Pritchett, E. Management of Atrial Fibrillation. New England Journal of Medicine.1992, 326(19), 1264-1271. 24. Castellano, J., Chinitz, J., Willner, J., Fuster, V. Mechanisms of Stroke in Atrial Fibrillation. Cardiac Electrophysiology Clinics. 2014 , 6(1), 5-15. 25. Wittkowsky, A. Effective anticoagulation therapy: defining the gap between clinical studies and clinical practice. American Journal of Managed Care. 2004;10(Suppl 10):S297–S306. 26. Friberg, L., Hammar, N., Ringh, M., Pettersson, H., Rosenqvist, M. Stroke prophylaxis in atrial fibrillation: who gets it and who does not?. European Heart Journal.2006, 27(16), 1954-1964. 27. Sabir, I., Khavandi, K., Brownrigg, J., Camm, A. Oral anticoagulants for Asian patients with atrial fibrillation. Nature Reviews Cardiology.2014, 11(5), 290-303. 28. Hsieh, F., Lien, L., Chen, S., Bai, C., Sun, M., Tseng, H. et al. Get With The Guidelines-Stroke Performance Indicators: Surveillance of Stroke Care in the Taiwan Stroke Registry. Circulation.2010, 122(11), 1116-1123. 29. Benjamin, E., Wolf, P., D’Agostino, R., Silbershatz, H., Kannel, W., Levy, D. Impact of Atrial Fibrillation on the Risk of Death. Circulation. 1998 , 98(10), 946-952. 30. Johnson, C., Nguyen, M., Roth, G., Nichols, E., Alam, T., Abate, D. et al. Global, regional, and national burden of stroke, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. The Lancet Neurology.2019, 18(5), 439-458. 31. D'Agostino, R., Wolf, P., Belanger, A., Kannel, W. Stroke risk profile: adjustment for antihypertensive medication. The Framingham Study. Stroke.1994, 25(1), 40-43. 32. O'Donnell, M., Xavier, D., Liu, L., Zhang, H., Chin, S., Rao-Melacini, P. et al. Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study. The Lancet.2010, 376(9735), 112-123. 33. Longenecker, J. Traditional Cardiovascular Disease Risk Factors in Dialysis Patients Compared with the General Population: The CHOICE Study. Journal Of The American Society of Nephrology.2002, 13(7), 1918-1927. 34. Lin, L., Lee, C., Yu, C., Tsai, C., Lai, L., Hwang, J. et al. Risk factors and incidence of ischemic stroke in Taiwanese with nonvalvular atrial fibrillation—A nation wide database analysis. Atherosclerosis.2011, 217(1), 292-295. 35. Stroke Risk in Atrial Fibrillation Working Group. Comparison of 12 risk stratification schemes to predict stroke in patients with nonvalvular atrial fibrillation. Stroke. 2008;39:1901-1910. 36. Gage, B., Waterman, A., Shannon, W., Boechler, M., Rich, M., Radford, M. Validation of Clinical Classification Schemes for Predicting Stroke. The Journal of the American Medical Assocation.2001, 285(22), 2864. 37. Lip, G., Lane, D. Stroke Prevention in Atrial Fibrillation. The Journal of the American Medical Assocation.2015, 313(19), 1950. 38. Lip, G., Nieuwlaat, R., Pisters, R., Lane, D., Crijns, H. Refining Clinical Risk Stratification for Predicting Stroke and Thromboembolism in Atrial Fibrillation Using a Novel Risk Factor-Based Approach. Chest.2010, 137(2), 263-272. 39. Kirchhof, P., Benussi, S., Kotecha, D., Ahlsson, A., Atar, D., Casadei, B. et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. European Heart Journal.2016, 37(38), 2893-2962. 40. January, C., Wann, L., Calkins, H., Chen, L., Cigarroa, J., Cleveland, J. et al. 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in Collaboration With the Society of Thoracic Surgeons. Circulation.2019, 140(2). 41. Lip, G., Banerjee, A., Boriani, G., Chiang, C., Fargo, R., Freedman, B. et al. Antithrombotic Therapy for Atrial Fibrillation. Chest.2018, 154(5), 1121-1201. 42. Ho, L., Brighton, T. warfarin, antiplatelet drugs and their interactions. Australian Prescriber.2002, 25(4), 81-85. 43. Björck, F., Renlund, H., Lip, G., Wester, P., Svensson, P., Själander, A. Outcomes in a warfarin-Treated Population With Atrial Fibrillation. JAMA Cardiology.2016, 1(2), 172. 44. Nutescu, E., Chuatrisorn, I., Hellenbart, E. Drug and dietary interactions of warfarin and novel oral anticoagulants: an update. Journal of Thrombosis and Thrombolysis.2011, 31(3), 326-343. 45. Teklay, G., Shiferaw, N., Legesse, B., Bekele, M. Drug-drug interactions and risk of bleeding among inpatients on warfarin therapy: a prospective observational study. Thrombosis Journal.2014, 12(1), 20. 46. Ge, B., Zhang, Z., Zuo, Z. Updates on the Clinical Evidenced Herb-warfarin Interactions. Evidence-Based Complementary and Alternative Medicine.2014, 2014, 1-18. 47. Tan, C., Lee, S. warfarin and food, herbal or dietary supplement interactions: A systematic review. British Journal Of Clinical Pharmacology.2020. 48. Jaffer, A., Bragg, L. (2003). Practical tips for warfarin dosing and monitoring. Cleveland Clinic Journal of Medicine.2003, 70(4), 361-371. 49. Yeh, C., Hogg, K., Weitz, J. Overview of the New Oral Anticoagulants. Arteriosclerosis, Thrombosis, and Vascular Biology.2015, 35(5), 1056-1065. 50. Wiggins, B., Dixon, D., Neyens, R., Page, R., Gluckman, T. Select Drug-Drug Interactions With Direct Oral Anticoagulants. Journal of the American College of Cardiology.2020, 75(11), 1341-1350. 51. Mekaj, A., Mekaj, Y., Duci, S., Miftari, E. New oral anticoagulants: their advantages and disadvantages compared with vitamin K antagonists in the prevention and treatment of patients with thromboembolic events. Therapeutics And Clinical Risk Management.2015, 967. 52. Connolly, S., Ezekowitz, M., Yusuf, S., Eikelboom, J., Oldgren, J., Parekh, A. et al. dabigatran versus warfarin in Patients with Atrial Fibrillation. New England Journal of Medicine.2009, 361(12), 1139-1151. 53. Patel, M., Mahaffey, K., Garg, J., Pan, G., Singer, D., Hacke, W. et al. rivaroxaban versus warfarin in Nonvalvular Atrial Fibrillation. New England Journal of Medicine.2011, 365(10), 883-891. 54. Granger, C., Alexander, J., McMurray, J., Lopes, R., Hylek, E., Hanna, M. et al. apixaban versus warfarin in Patients with Atrial Fibrillation. New England Journal of Medicine.2011, 365(11), 981-992. 55. Giugliano, R., Ruff, C., Braunwald, E., Murphy, S., Wiviott, S., Halperin, J. et al. edoxaban versus warfarin in Patients with Atrial Fibrillation. New England Journal of Medicine.2013, 369(22), 2093-2104. 56. Ruigómez, A., Vora, P., Balabanova, Y., Brobert, G., Roberts, L., Fatoba, S. et al. Discontinuation of non-Vitamin K antagonist oral anticoagulants in patients with non-valvular atrial fibrillation: a population-based cohort study using primary care data from The Health Improvement Network in the UK. British Medical Journal Open.2019, 9(10), e031342. 57. Hori, M., Connolly, S., Zhu, J., Liu, L., Lau, C., Pais, P. et al. dabigatran Versus warfarin. Stroke.2013, 44(7), 1891-1896. 58. Wong, K., Hu, D., Oomman, A., Tan, R., Patel, M., Singer, D. et al. rivaroxaban for Stroke Prevention in East Asian Patients From the ROCKET AF Trial. Stroke.2014, 45(6), 1739-1747. 59. Hori, M., Matsumoto, M., Tanahashi, N., Momomura, S., Uchiyama, S., Goto, S. et al. rivaroxaban vs. warfarin in Japanese Patients With Atrial Fibrillation. Circulation Journal.2012, 76(9), 2104-2111. 60. Yamashita, T., Koretsune, Y., Yang, Y., Chen, S., Chung, N., Shimada, Y. et al. edoxaban vs. warfarin in East Asian Patients With Atrial Fibrillation- an ENGAGE AF-TIMI 48 subanalysis. Circulation Journal.2016, 80(4), 860-869. 61. Goto, S., Zhu, J., Liu, L., Oh, B., Wojdyla, D., Aylward, P. et al. Efficacy and Safety of apixaban Compared with warfarin for Stroke Prevention in Patients with Atrial Fibrillation from East Asia: a subanalysis of the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial. American Heart Journal.2014, 168(3), 303-309. 62. Kim, H., Choi, E., Park, C., Cha, M., Lee, S., Kwon, J., Oh, S. Effectiveness and safety of non-vitamin K antagonist oral anticoagulants in octogenarian patients with non-valvular atrial fibrillation. PLOS ONE.2019, 14(3), e0211766. 63. Lee, C., Gerds, T., Carlson, N., Bonde, A., Gislason, G., Lamberts, M. et al. Risk of Myocardial Infarction in Anticoagulated Patients With Atrial Fibrillation. Journal of the American College of Cardiology.2018, 72(1), 17-26. 64. Sjögren, V., Byström, B., Renlund, H., Svensson, P., Oldgren, J., Norrving, B., Själander, A. Non-vitamin K oral anticoagulants are non-inferior for stroke prevention but cause fewer major bleedings than well-managed warfarin: A retrospective register study. PLOS ONE.2017, 12(7), e0181000. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/19410 | - |
dc.description.abstract | 研究背景: 心房顫動(Atrial fibrillation,AF)是臨床上常見的一種心律不整之一。目前台灣包含dabigatran、apixaban、edoxaban、rivaroxaban等新型口服抗凝血劑(new oral anticoagulants, NOACs)均已被核准用來治療非瓣膜性心房顫動患者,以預防中風及全身性栓塞的發生,然而不同NOACs需依據腎功能選擇其劑量。對於真實世界之亞洲族群NOACs考量不同腎功能區間相對劑量選擇之療效及安全性評估研究仍相對欠缺。 研究目的: 本研究旨在評估台灣現實狀況下新型口服抗凝血劑依據建議處方劑量與療效及安全性之關聯,以提升臨床使用NOACs藥物安全性與可行性。 研究方法: 本研究採回溯性觀察研究, 2014年1月1日至2018年12月31日間於台北市立聯合醫院仁愛及和平婦幼院區門診就診首次使用dabigatran、edoxaban、rivaroxaban或wafarin做治療之AF病人,這些病人首次使用NOACs 治療前3個月內曾監測肌酸酐(serum creatinine)、且連續治療滿30天才被納入研究中,並排除NOACs用於其他適應症、曾經進行心臟瓣膜置換手術或過去病史紀錄不完全、連續治療未滿30天之患者。根據2018年歐洲心律協會治療指引(European Heart Rhythm Association guidelines)對處方劑量進行評估、分組(符合建議劑量、高於建議劑量、低於建議劑量、使用warfarin等4組),以Cox 比例風險模式(Cox proportional hazards model)評估各組於追蹤期間發生缺血性中風及全身性栓塞、總死亡、急性心肌梗塞、顱內出血、腸胃道出血等事件的比例。研究追蹤病人直至出現任何前述事件、停止藥物治療或至研究結束日期為止。 研究結果: 本研究共收納999人,符合建議劑量的比例為33.4%,反之,61.2%為低於建議劑量。高於建議劑量組、低於建議劑量、符合建議劑量及warfarin組用藥天數中位數為259、462、441及295天。則低於建議劑量及warfarin兩組分別與符合建議劑量為參考組比較,其各事件之風險比[95% 信賴區間]為:缺血性中風及全身性栓塞之風險比分別為0.73 [0.40-1.33] 及0.97 [0.41-2.27]; 總死亡之風險比分別為1.25[0.71-2.21] 及1.47[0.70-3.06]; 急性心肌梗塞之風險比分別為0.75 [0.41-1.37] 及0.86 [0.40-1.83] ; 顱內出血之風險比分別為2.04 [0.38-11.04] 及 1.31 [0.12-14.57] ; 腸胃出血之風險比分別為0.40 [0.15-1.07] 及 0.98[0.28-3.43]。 結論: 本研究結果顯示不論是腎功能正常或異常,均有新型口服抗凝血藥處方劑量不適當之情形,其中以處方劑量低於建議者居多,尤以rivaroxaban為最。低於建議劑量組及warfarin組分別與符合建議劑量組比較,不論是缺血性中風或全身性栓塞風險、急性心肌梗塞、顱內出血、腸胃道出血及總死亡風險,均無統計上顯著差異,可能受限於樣本數較少,目前仍不足以下定論: 是否亞洲族群給予低於準則建議的藥量在療效及安全性上,即可與給予符合準則建議劑量組相當,亦或會因為劑量給予不足增加相對風險。因此,未來仍尚待更大型研究進一步證實。在整體用藥天數分析上可以看到,符合建議劑量的組別及低於建議劑量組整體接受藥物治療的時間較高於建議劑量組和warfarin組長,能夠長期接受藥物治療而不中斷也是後續研究重要議題之一。 | zh_TW |
dc.description.abstract | Background Atrial fibrillation (AF) is the most common cardiac arrhythmia. Non vitamin K antagonist oral anticoagulants (NOACs) including dabigatran, apixaban, edoxaban, rivaroxaban and other new oral anticoagulants have been approved to treat patients with non-valvular atrial fibrillation(NVAF) to prevent stroke and systemic embolism in Taiwan. Clinical decisions on how to treat an Af patient who needs NOACs require the assessment of renal function. Only limited evidence of renal function has been assessed and considered for recommending NOAC dosage in Asia. Objectives The relationship between the dosage and efficacy and safety of the new oral anticoagulants is investigated according to the guidelines in real-world clinical practice in Taiwan. Methods We conducted a retrospective cohort study of patients diagnosed with NVAf at Taipei City Hospital Renai Branch and Taipei City Hospital Heping Fuyou Branch from January 2014 to December 2018. Patients who had their first prescription of NOACs including dabigatran, rivaroxaban, edoxaban, apixaban, or warfarin treatment from January 1, 2014 to December 31, 2018 were included in the study. Additionally, patients were included only if they had a documented renal function laboratory test (serum creatinine) within 3 months before the index prescription date. Patients received NOACs for less than 30 days and/or for other indications were excluded. The follow-up period was from the index date until the first occurrence of one of the following events, any study outcome、medication discontinued and the end date of study (December 31, 2019). The appropriateness of the prescription was assessed according to the 2018 European Heart Rhythm Association Guidelines. Patients were classified into appropriately dosed、inappropriately dosed (overtreated or undertreated) based on these dosage guidelines. Cox regression analysis was used to estimate adjusted hazard ratios (HR) and 95% confidence intervals (CI) for evaluating the dosage effect on the risks of the primary outcomes of stroke, systemic embolism(SE), all cause mortality, acute myocardial infarction (AMI), intracranial hemorrhage(ICH), and gastrointestinal bleeding(GIB). Result A total of 999 patients were included in this study, of whom 33.4% were appropriate, 61.2% were undertreated. The median follow-up periods for overtreated, appropriate-dosed, undertreated and warfarin groups were 259、462、441 and 295 days, respectively. For comparing undertreated group and warfarin group repsecitvely to appropriate-dosed group, the two HRs [95% CI] for stroke/systemic embolism were 0.73 [0.40-1.33] and 0.97 [0.41-2.27]; those for all-cause mortality 1.25[0.71-2.21] and 1.47[0.70-3.06]; those for AMI 0.75 [0.41-1.37] and 0.86 [0.40-1.83]; those for ICH 3.74 [0.59-23.76] and 2.76 [0.23-32.84]; and those for GIB 0.40 [0.15-1.07] and 0.98[0.28-3.43]. Conclusion Our results showed that inappropriate NOAC dosing occurred in patients with normal and insufficient renal function. There was a high prevalence of low-dose NOAC prescription (undertreated) among the study cohort, especially for rivaroxaban. Our results also indicated that there were no statistically significant differences in stroke/SE、all cause mortality、AMI、ICH and GIB between the appropriate-dosed and the undertreated groups. Because of small sample size, we cannot conclude that there are no differences in efficacy and safety between NOAC dosages. Further large-scale studies in Asian population are needed. It can be seen that the overall medication days were different between the appropriate-dosed and the overtreated groups. It is also an important topic for future research how to receive medication for a long time without interruption. | en |
dc.description.provenance | Made available in DSpace on 2021-06-08T01:57:43Z (GMT). No. of bitstreams: 1 U0001-1708202009582300.pdf: 2241709 bytes, checksum: fea08571ebd659c1e5068f94ce073312 (MD5) Previous issue date: 2020 | en |
dc.description.tableofcontents | 口試委員會審定書…………….…………………….……………………..i 誌謝…………………………………………………………………….......ii 中文摘要……………………………………………………………..……iii 英文摘要…………………………………………………………..……….v 第一章 緒論……….…………………………………………..................1 第二章 文獻回顧…………………………………………….....………..3 2.1 心房顫動簡介.…………………...……………..………….......3 2.2 心房顫動與腦中風及血栓栓塞………….....…..………....…..3 2.2.1 心房顫動和中風之關聯性……….…………..……...……3 2.2.2 相關危險因子……..………….........…………...…………4 2.2.3 中風及栓塞風險評估....………………….…….…………4 2.3 缺血性腦中風預防之藥物治療..………....…..……………….5 2.3.1 藥物治療建議啟用時機………….……….....……………5 2.3.2 Wafarin簡介...……………………..…...............…………5 2.3.3 新型口服抗凝血劑簡介………………..……...…….……6 第三章 研究方法………..……………….…………………………........9 3.1 研究假說…………….…...…….…………………...…...….…..9 3.2 研究資料…………….……………………………...…...….…..9 3.3 研究變項…………………………………………..…...…..….. 9 3.4 主要結果變項………………………............................……....11 3.5 研究流程………………………………………..…….....…….14 3.6 統計分析………………………………………..…….....…….15第四章 研究結果………..……………………………………………...16 4.1 研究對象及分組.…...………………………...…….....………16 4.2 基本資料分析…...…………………………..............………...17 4.3 各事件發生率與用藥天數比較……………...……........…….20 4.4 缺血性中風及全身性栓塞風險比較……………...........…….20 4.5 總死亡率之風險比較...………………………...…….....…….21 4.6 急性心肌梗塞之風險比較……………………..…….....…….21 4.7 顱內出血之風險比較………………………...………....…….22 4.8 主要腸胃道出血之風險比較………………..….…...………. 22 4.9 NOACs組與warfarin組風險比較……………………...…… 23 4.10 Dabigatran rivaroxaban組與warfarin組風險比較...……. 24 第五章 討論……...………..…………………………..………………..53 5.1 NOACs處方劑量探討.………………………...…….....…….53 5.2 缺血性中風及全身栓塞事件風險討論………….……..…….54 5.3 總死亡事件風險討論…………..……………...…...…………55 5.4 急性心肌梗塞事件風險討論………………...…...…………..56 5.5 顱內出血及腸胃道出血事件風險討論………………...…….57 5.6 研究限制與優勢…………..……………………...…...…...….58 第六章 結論…………..…..……………………………………..……..60 參考文獻………………………………………………………….……...61 | |
dc.language.iso | zh-TW | |
dc.title | 心房顫動患者使用新型口服抗凝血劑不同劑量之療效及安全性評估 | zh_TW |
dc.title | Evaluation of Efficacy and Safety of the Different Dosages of New Oral Anticoagulants in Patients with Atrial Fibrillation | en |
dc.type | Thesis | |
dc.date.schoolyear | 108-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 戴政,陳秀熙,杜裕康,蘇登煌 | |
dc.subject.keyword | apixaban,dabigatran,劑量選擇,edoxaban,非維他命K拮抗劑口服抗凝血劑,rivaroxaban, | zh_TW |
dc.subject.keyword | apixaban,dabigatran,dosage choice,edoxaban,non vitamin K antagonist oral anticoagulants,rivaroxaban, | en |
dc.relation.page | 66 | |
dc.identifier.doi | 10.6342/NTU202003686 | |
dc.rights.note | 未授權 | |
dc.date.accepted | 2020-08-17 | |
dc.contributor.author-college | 公共衛生學院 | zh_TW |
dc.contributor.author-dept | 流行病學與預防醫學研究所 | zh_TW |
顯示於系所單位: | 流行病學與預防醫學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
U0001-1708202009582300.pdf 目前未授權公開取用 | 2.19 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。